tradingkey.logo
搜尋

Precigen Inc

PGEN
添加自選
4.150USD
+0.070+1.72%
收盤 05/13, 16:00美東報價延遲15分鐘
1.45B總市值
虧損本益比TTM

Precigen Inc

4.150
+0.070+1.72%
查看詳細走勢圖
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+1.72%

5天

-5.68%

1月

-0.48%

6月

+7.51%

今年開始到現在

-0.72%

1年

+207.41%

TradingKey Precigen Inc股票評分

單位: USD 更新時間: 2026-05-13

操作建議

Precigen Inc當前公司基本面數據相對穩定,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在藥品行業排名73/156位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為9.50。中期看,股價處於下降通道。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Precigen Inc評分

相關信息

行業排名
73 / 156
全市場排名
191 / 4487
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Precigen Inc亮點

亮點風險
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
業績高增長
公司營業收入穩步增長,連續3年增長55.57%
業績增長期
公司處於發展階段,最新年度總收入9.68M美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入9.68M美元
估值合理
公司最新PE估值-3.43,處於3年歷史合理位
機構加倉
最新機構持股270.08M股,環比增加5.66%
PRFDX持倉
明星投資者PRFDX持倉,最新持倉17.96K股
活躍度降低
近期活躍度降低,過去20天平均換手率-0.23

分析師目標

基於 3 分析師
買入
評級
9.500
目標均價
+126.19%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Precigen Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Precigen Inc簡介

Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
公司代碼PGEN
公司Precigen Inc
CEOSabzevari (Helen)
網址https://precigen.com/
KeyAI